New developments in Valeant’s bid for Allergan

Valeant Pharmaceuticals, the big Canadian-based group that has owned Bausch & Lomb since last year, sent a letter to Allergan's shareholders on Oct. 27 stating that it was prepared to increase the proposed price of its takeover offer again from $72 to $200 per share. The new offer coincided with ...

To continue reading this article subscribe now


Become a member today for full access from just €6,70 a week!

Buying a membership today will give you:

  • Our executive edition of Eyewear Intelligence (Regular PDF format or E-Format) - the must-read for all decision-makers in the industry
  • Weekly E-mail Briefing from the Chief Editor with the lastest analysis and most important industry developments
  • Case studies and best practices on business challenges
  • Guest chronicles, interviews, insights from industry experts and leaders that are shaping the future of the industry
  • Unlimited access to - all insight, analysis and statistics available online
  • Access to over 11,500 articles and analyses in the archive
  • Personal library to save articles and track your key content
  • Powerful search and intuitive navigation
  • Breaking news

Already an Eyewear Intelligence subscriber? Sign in here.